Different Doses of Vitamin A and Childhood Morbidity and Mortality
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00168584|
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : September 15, 2005
|Condition or disease||Intervention/treatment||Phase|
|Mortality Morbidity||Drug: Vitamin A||Phase 4|
Vitamin A supplementation (VAS) to children above 6 months of age reduces all-cause mortality with 23 %1 to 30 % in low-income countries. WHO recommends VAS at vaccination contacts. The currently recommended doses to be administered every 3-6 months are 100,000 IU for infants between 6 and 11 months of age and 200,000 IU for children 12 months and older. There is no clear evidence that a large dose is better than a small dose, the tendency being the opposite in the two studies of different doses of VAS that have been published so far.
With the global effort to eradicate polio, national immunization days with oral polio vaccine (OPV) offer an additional opportunity to provide vitamin A. In Guinea-Bissau, a combined OPV and VAS campaign took place in November 2002. Given the uncertainty about the best dose of VAS, we aimed to examine whether the dose of vitamin A currently recommended by WHO or half this dose gives a better protection against childhood morbidity and mortality.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||5400 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomised Study of the Impact of Different Doses of Vitamin A on Childhood Morbidity and Mortality|
|Study Start Date :||November 2002|
|Study Completion Date :||August 2003|
- Rotavirus infection
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00168584
|Bandim Health Project, Apartado 861|
|Principal Investigator:||Peter Aaby, DMSc||Bandim Health Project|